Designation: RJ2.2.5

CLS order number: Cryovial: 300360

gDNA: 300360GD05



Origin are 10-1			
Origin and General Cha			
Organism:	Homo sapiens (human)		
Ethnicity:	African		
Age:	11 years of age		
Gender:	Male		
Tissue:	Hematopoietic system		
Morphology:	B-Lymphoblast		
Growth Properties:	Suspension		
Description:	Established from an 11-year-old boy with Burkitt lymphoma. This cell line is a variant of Burkitt cell line Raji (CLS order number 330359; This cell line is deficient in expression of HLA Class II antigen. RJ2.2.5 is deleted at least in 1 allele of the MHC Class II transactivator (CIITA), the other allele of CIITA is also affected but not completely deleted. RJ2.2.5 is EBNA positive of Epstein Barr virus.		
References:	Acolla RS. Human B cell variants immunoselected against a single la antigen subset have lost expression of several la antigen subsets. J.Exp. Med. 157:1053-1058 (1983) For further information see Cellosaurus, Accession no. CVCL_3414		
	A list of further relevant literature can be requested at CLS.		
Culture Conditions and	l Handling		
Culture Medium:	RPMI 1640 with 10% FBS (MG-70, CLS order number 820700).		
Subculturing:	Maintain culture between 3 to 9 x10 <sup>5</sup> cells/ml; A maximum density of 2 x10 <sup>6</sup> cells/ml is possible. Incubate at 5% CO <sub>2</sub> , 37°C.		
Seeding density:	3x10 <sup>5</sup> /ml		
Fluid Renewal:	2 times weekly		
Freeze Medium:	CM-1 (CLS order number: 800125, 25ml, 800150, 50ml)		
Freezing recovery:	Fast (48 hours)		
Sterility:	Mycoplasma specific PCR: negative Cell-based Plasmotest: negative		
Biosafety Level:	2 (parental line RAJI is BSL1)		
Shipping requirements:	Certain cell lines, in particular virally transformed ones (e.g. infectious EBV-transformed LCL or Burkitt lymphoma) or those carryiong infectious microbial agents, are restricted in their distribution according to German law for the protection against infections (Infektionsschutzgesetz, IfSG). These cell lines can only be distributed to costumers holding a valid permit of the respective authority according to IfSG § 44. The permit must be presented to CLS before shipment. For exceptions see IfSG § 45. Costumers outside Germany must provide a legal permit, adequate to the German IfSG, issued by their respective authority for importation and distribution. Costumers from the US may require a permit issued by the office of Public Health and Safety, CDC permit6 0.728 for importation and distribution. A copy of the respective permit must be provided to CLS before shipment can be initiated.		
Safety precautions:	If the cryovial is planned to be stored in liquid nitrogen and to be thawed in the future, special safety precautions should be followed:  Protective gloves and clothing should be used and a facemask or safety goggles must be worn when transferring frozen samples into or removing from the liquid nitrogen tank.		

	The removal of a cryovial from liquid nitrogen may result in the explosion of the frozen vial creating flying fragments.  Caputo, J.L. Biosafety procedures in cell culture. J. Tissue Cult. Methods 11:223-227, 1988. ATCC Quality Control Methods for Cell Lines, 2nd edition, 1992.		
Special Features of the	Cell Line		
Karyotype:	46, hypodiploid		
Surface antigens:	CD10+, CD19+		
HLA-typing:	Class I A*03:01:01 B*15:10:01 C*03:04:02,*04:01:01	Class II DRB1*03:01:01,*10:01:01 DQA1*01:05:01,*05:01:01 DQB1*02:01:01,*05:01:01 DPB1*01:01:01 E*01:01:01	
DNA Profile (STR):	Amelogenin: X.Y CSF1PO: 10,12 D13S317: 13,13 D16S539: 8,11 D5S818: 10,10 D7S820: 10,10 THO1: 6,7 TPOX: 8,13	vWA: 16,19 D3S1358: 15,16 D21S11: 28,31 D18S51: 17 Penta E: 5,13 Penta D: 3.2,9 D8S1179: 14,15 FGA: 19,27	
Possible applications:	Analysis of B cell surface antigens, testing of cytotoxic drugs, mutational analysis, analysis of apoptotic mechanisms, HLA-typing		

Certificate of Analysis:	The Certificate of Analysis for each batch can be requested by e-mail at	
	service@clsgmbh.de.	

Recommendations for handling of cells growing in suspension following delivery			
Cryopreserved cells	The cells come deep-frozen shipped on dry ice. Please make sure that the vial is still frozen.  If immediate culturing is not intended, the cryovial(s) must be stored below -150°C after arrival.  If immediate culturing is intended, please follow these instructions:  Quickly thaw by rapid agitation in a 37°C water bath within 40-60 seconds. The water bath should have clean water containing an antimicrobial agent. As soon as the sample has thawed, remove the cryovial from the water bath. Note: A small ice clump should still remain and the vial should still be cold.  From now on, all operations should be carried out under aseptic conditions.  Transfer the cryovial to a sterile flow cabinet and wipe with 70% alcohol. Carefully open the vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of culture medium (room temperature). Resuspend the cells carefully. Centrifuge at 300xg for 3 min and discard the supernatant. The centrifugation step may be omitted, but in this case the remains of the freeze medium have to be removed 24 hours later.  Resuspend the cells carefully in 10ml fresh cell culture medium and transfer them into one T25 cell culture flask. All further steps are described in the Subculture section.		

Warranty:  CLS warrants for a high cell viability and culture performance only if the product(s (are) stored and cultured according to the information described above. Using cell media and supplements other than the ones recommended in this product information may result in satisfactory proliferation and viabilities. CLS, however, does not wark cell recovery, proliferation and function if differing formulations are employed.	l culture ation
--	--------------------

## Disclaimer:

The customer shall not be entitled to employ this product for purposes other than research. Commercial utilization shall not be permitted; in particular, the cell line, its components or materials made therefrom shall not be sold or transferred to any third party. In addition, the term 'Commercial use' shall mean any activity by a party for consideration and may include, but is not limited to, use of the product or its components in manufacturing, for providing services, e.g. fee for service testing, in quality control or assurance processes within the manufacturing of products for sale, for therapeutic, diagnostic or prophylactic purposes, or for resale.